Profile: iCo Therapeutics Inc. is a reprofiling company focused on redosing or reformulating drugs. Our iCo-007 is an inhibitor targeting C-raf kinase messenger ribonucleic acid, for the treatment of retinal neovascular diseases such as diabetic retinopathy. Our iCo-008 is a human immunoglobulin monoclonal antibody targeting eotaxin-1, a member of the chemokine family of proteins, that acts as messenger molecules between the cells of the immune system. Our iCo-009 is an oral reformulation of Amphotericin B for sight and life threatening diseases.